SCHEMBL3835932

SCHEMBL3835932

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(CN(CCCN2CCOCC2)C(=O)Nc2ccc3ncccc3c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.48
TSHR P16473 2/20 0.45
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
ALDH1A1 P00352 3/20 0.43
CD274 Q9NZQ7 1/20 0.42
ROCK2 O75116 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CASR P41180 2/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NAMPT P43490 3/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2497103 0.88 HDAC1 (0.50) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL2477829 0.86 HSD17B10 (0.51) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL3832709 0.86 USP2 (0.55) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL3836032 0.86 OPRM1 (0.49) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL2479082 0.86 OPRM1 (0.51) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL3835829 0.86 ALDH1A1 (0.50) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL2497298 0.86 HDAC1 (0.52) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL2473939 0.86 TSHR (0.60) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL4396390 0.85 OPRM1 (0.50) USP2TSHROPRM1OPRD1ALDH1A1
SCHEMBL2475705 0.85 KDM1A (0.51) USP2TSHROPRM1OPRD1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 USP2 719/4885TSHR 2476/4885OPRM1 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.